سعر التارجو Altargo‏ 1% مرهم 2026

• Most commonly reported adverse reaction: application site irritation (about 1% of patients).International label, same formulation · European Medicines Agency (EMA)

• Hypersensitivity to retapamulin or any excipient.International label, same formulation · European Medicines Agency (EMA)

• Stop if sensitisation or severe local irritation occurs; keep away from eyes and mucous membranes (epistaxis reported with nasal use); avoid ingestion; do not use for abscesses or infections known or likely due to MRSA; prolonged use may cause overgrowth of non-susceptible organisms; contains butylated hydroxytoluene (local skin reactions).International label, same formulation · European Medicines Agency (EMA)

• Other topical medicinal products on the same skin areaConcurrent application has not been studied and is not recommended. Retapamulin strongly inhibits CYP3A4 in vitro, but clinically important systemic interactions are not expected given low plasma levels.European Medicines Agency (EMA)

• No clinical data on exposed pregnancies; animal studies showed reproductive toxicity after oral dosing. Use in pregnancy only when topical antibacterial therapy is clearly indicated and preferable to a systemic antibacterial.International label, same formulation · European Medicines Agency (EMA)
• Unknown whether excreted in human milk; minimal systemic exposure, so infant exposure likely negligible; decide on breastfeeding vs therapy by benefit.International label, same formulation · European Medicines Agency (EMA)

English text not available for this section.